Skip to content

Skip to secondary menu

Jehovah’s Witnesses


Cardiothoracic and Vascular Surgery

Management and Optimization of Hemostasis

Case 12-2016 ascending aorta dissection in a Jehovah's Witness patient on warfarin.

Silvetti S, Crivellari M, Castiglioni A, Landoni G, Zangrillo A, Alfieri O, Koster A, Faraoni D, Bolliger D, Tanaka KA

Source‎: J Cardiothorac Vasc Anesth 2016;30(6):1709-15.

Indexed‎: PubMed 27639716

DOI‎: 10.1053/j.jvca.2016.02.029

Alternatives to allogeneic platelet transfusion.

Desborough MJ, Smethurst PA, Estcourt LJ, Stanworth SJ

Source‎: Br J Haematol 2016;175(3):381-92.

Indexed‎: PubMed 27650431

DOI‎: 10.1111/bjh.14338

Fibrinogen supplementation after cardiac surgery: insights from the zero-plasma trial (ZEPLAST).

Ranucci M, Baryshnikova E

Source‎: Br J Anaesth 2016;116(5):618-23.

Indexed‎: PubMed 26893405

DOI‎: 10.1093/bja/aev539

Recombinant activated factor VII significantly reduces transfusion requirements in cardiothoracic surgery.

Omar HR, Enten G, Karlnoski R, Ching YH, Mangar D, Camporesi EM

Source‎: Drugs R D 2015;15(2):187-94.

Indexed‎: PubMed 25862216

DOI‎: 10.1007/s40268-015-0093-9

Randomized, double-blinded, placebo-controlled trial of fibrinogen concentrate supplementation after complex cardiac surgery.

Ranucci M, Baryshnikova E, Crapelli GB, Rahe-Meyer N, Menicanti L, Frigiola A; Surgical Clinical Outcome REsearch (SCORE) Group.

Source‎: J Am Heart Assoc 2015;4(6):e002066.

Indexed‎: PubMed 26037084

DOI‎: 10.1161/JAHA.115.002066

First-line therapy with coagulation factor concentrates combined with point-of-care coagulation testing is associated with decreased allogeneic blood transfusion in cardiovascular surgery: a retrospective, single-center cohort study.

Görlinger K, Dirkmann D, Hanke AA, Kamler M, Kottenberg E, Thielmann M, Jakob H, Peters J.

Source‎: Anesthesiology 2011;115(6):1179-1191.

Indexed‎: PubMed 21970887

DOI‎: 10.1097/ALN.0b013e31823497dd

Effects of fibrinogen concentrate as first-line therapy during major aortic replacement surgery: a randomized, placebo-controlled trial.

Rahe-Meyer N, Solomon C, Hanke A, Schmidt DS, Knoerzer D, Hochleitner G, Sørensen B, Hagl C, Pichlmaier M.

Source‎: Anesthesiology 2013;118(1):40-50.

Indexed‎: PubMed 23249928

DOI‎: 10.1097/ALN.0b013e3182715d4d

Drug, devices, technologies, and techniques for blood management in minimally invasive and conventional cardiothoracic surgery: a consensus statement from the International Society for Minimally Invasive Cardiothoracic Surgery (ISMICS) 2011.

Menkis AH, Martin J, Cheng DC, Fitzgerald DC, Freedman JJ, Gao C, Koster A, Mackenzie GS, Murphy GJ, Spiess B, Ad N.

Source‎: Innovations (Phila) 2012;7(4):229-41.

Indexed‎: PubMed 23123988

DOI‎: 10.1097/IMI.0b013e3182747699

Can topical application of tranexamic acid reduce blood loss in thoracic surgery? A prospective randomised double blind investigation.

Dell'Amore A, Caroli G, Nizar A, Cassanelli N, Luciano G, Greco D, Dolci G, Bini A, Stella F.

Source‎: Heart Lung Circ 2012;21(11):706-10.

Indexed‎: PubMed 22842057

DOI‎: 10.1016/j.hlc.2012.06.016

Haemostatic therapy in coronary artery bypass graft patients with decreased platelet function: comparison of fibrinogen concentrate with allogeneic blood products.

Solomon C, Schöchl H, Hanke A, Calatzis A, Hagl C, Tanaka K, Rahe-Meyer N.

Source‎: Scand J Clin Lab Invest 2012;72(2):121-8.

Indexed‎: PubMed 22233480

DOI‎: 10.3109/00365513.2011.643818

Bleeding in a Jehovah's Witness patient undergoing a redo aortic valve replacement controlled with cryoprecipitate and a prothrombin complex concentrate.

Robblee JA, Wilkes PR, Dickie SJ, Rubens FD, Bormanis J.

Source‎: Can J Anaesth 2012;59(3):299-303.

Indexed‎: PubMed 22161243

DOI‎: 10.1007/s12630-011-9647-7

Tranexamic acid reduces blood loss after off-pump coronary surgery: a prospective, randomized, double-blind, placebo-controlled study.

Wang G, Xie G, Jiang T, Wang Y, Wang W, Ji H, Liu M, Chen L, Li L.

Source‎: Anesth Analg 2012;115(2):239-43.

Indexed‎: PubMed 21737704

DOI‎: 10.1213/ANE.0b013e3182264a11

Role of recombinant factor VIIa in the treatment of intractable bleeding in vascular surgery.

Končar IB, Davidović LB, Savić N, Sinđelić RB, Ilić N, Dragas M, Markovic M, Kostic D.

Source‎: J Vasc Surg 2011;53(4):1032-7.

Indexed‎: PubMed 21215579

DOI‎: 10.1016/j.jvs.2010.07.075

Safety and efficacy of recombinant activated factor VII: a randomized placebo-controlled trial in the setting of bleeding after cardiac surgery.

Gill R, Herbertson M, Vuylsteke A, Olsen PS, von Heymann C, Mythen M, Sellke F, Booth F, Schmidt TA.

Source‎: Circulation 2009;120(1):21-7.

Indexed‎: PubMed 19546387

DOI‎: 10.1161/CIRCULATIONAHA.108.834275

The medical section of is designed as an informational resource primarily for use by clinicians and other health-care professionals. It provides neither medical advice nor treatment recommendations and does not substitute for an appropriately qualified health-care provider. The clinical literature cited is not published by Jehovah’s Witnesses, but it outlines transfusion-alternative strategies that might be considered. It is the responsibility of each qualified health-care provider to maintain awareness of new information, discuss options for care, and assist patients in making choices in accord with their medical condition, wishes, values, and beliefs. Not all listed strategies are appropriate or acceptable to all patients.

Patients: Always seek the advice of your doctor or other qualified health-care provider regarding medical conditions or treatments. Check with a doctor if you suspect you are ill.

The use of this website is governed by its terms of use.